Three major COVID-19 vaccine makers — Pfizer, Moderna and Novavax — issued separate statements Wednesday defending their products and promising more transparency after President Donald Trump publicly questioned why companies were not sharing results. Pfizer said its COVID-19 vaccine data appear in more than 600 peer-reviewed publications, Moderna cited effectiveness studies in more than 5 million people since 2021, and all three companies linked their responses to the legacy of Operation Warp Speed.

Why It Matters To Oncology

• For clinicians focused on drug discovery, the most relevant signal is Moderna's effort to tie mRNA's pandemic track record to oncology, arguing the platform's promise extends beyond infectious disease into cancer.

• The episode underscores how political scrutiny of COVID-19 can spill over into broader perceptions of mRNA science, a modality now central to multiple oncology pipelines.

• Any erosion in public or federal support for mRNA could affect capital flows, partnerships and regulatory confidence around cancer vaccine and immunotherapy development.

The Financials

• Moderna highlighted that the U.S. recently cancelled about $500 million in funding for 22 mRNA vaccine programs, a policy shift with potential read-through for platform companies working in oncology and rare disease.

• Pfizer responded with a scale argument, pointing to more than 600 peer-reviewed publications and roughly 200 news releases, studies and updates on its COVID-19 vaccine and treatment since March 2020.

• The immediate issue is reputational, but the downstream stakes include government support, investor sentiment and future platform valuation for mRNA-enabled drug discovery.

What They're Saying

• Pfizer CEO Albert Bourla called U.S. development of mRNA vaccines a “profound public health achievement,” saying Operation Warp Speed helped save more than 14 million lives globally.

• Moderna said it was “immensely proud” of its role in Operation Warp Speed and stressed that “the promise of mRNA is immense,” including in cancer.

• Novavax, whose shot is the only non-mRNA COVID-19 vaccine available in the U.S., said Warp Speed enabled American scientific ingenuity to come together.

• Trump wrote that he had seen “extraordinary” information from Pfizer and others and demanded companies show their data “NOW, to CDC and the public.”

What's Next

• Pfizer said it plans to post additional COVID-19 studies by month's end, offering a near-term test of how much extra transparency companies are willing to provide.

• The broader policy backdrop remains unstable following upheaval at the CDC and narrower FDA approval of updated COVID-19 shots than under the prior administration.

• For oncology watchers, the key question is whether pressure on vaccine evidence standards remains confined to COVID-19 or broadens into tougher scrutiny of mRNA-based cancer programs.